Events Archives - Page 69 of 128

3 minute read

New Data from Phase 1/2 Trial Of INO-3107 For The Treatment Of Recurrent Respiratory Papillomatosis Presented At ABEA During COSM 2023

May 8, 8:04 AM

Oral presentation provided new combined safety and immunogenicity data from both cohorts (standard and side-port needles) Data indicates INO-3107 was well tolerated and has the potential to provide

INO

2 minute read

Warren Buffett To Share Wisdom With Berkshire Hathaway Shareholders As Bank Failures Rattle Market

By Wayne Duggan

May 5, 11:19 AM

Billionaire investing legend Warren Buffett is set to host the Berkshire Hathaway, Inc (NYSE: BRK-A) (NYSE: BRK-B) annual shareholder meeting in his hometown of Omaha, Nebraska, on Saturday.

AAPL

2 minute read

Cocrystal Pharma Presents New Data From Its CC-42344 Phase 1 Influenza A Study At The 7th Annual ISIRV Antiviral Group Conference

By Happy Mohamed

May 4, 5:05 PM

Cocrystal Pharma, Inc. (NASDAQ:COCP) (Cocrystal or the Company) announces that new data from its CC-42344 Phase 1 influenza A Study was presented today by Sam Lee, Ph.D., President and co-CEO, at the 7th Annual

COCP

1 minute read

Spruce Biosciences To Present Findings On Retrospective Analysis Of Completion Rates For CAH Studies At Pediatric Endocrine Society 2023 Annual Meeting

By Happy Mohamed

May 4, 5:01 PM

Mitchell Geffner, M.D., to Present on May 7, 2023 from 12:30 pm – 2 pm PT Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies

SPRB

3 minute read

Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted For Oral Presentation At The 26th Annual Meeting Of The American Society Of Gene And Cell Therapy

By Happy Mohamed

May 4, 12:31 PM

Immix Biopharma, Inc. (NASDAQ:IMMX) ("ImmixBio", "Company", "We" or "Us") today announced that updated NXC-201 clinical data has been selected for presentation at the upcoming 26th

IMMX

3 minute read

Karyopharm Announces Presentation Of Interim Data From Phase 2 Study Of Single-Agent Eltanexor In Relapsed/Refractory Higher-Risk Myelodysplastic Neoplasms At 17th International Congress On MDS

By Benzinga Newsdesk

May 3, 8:48 AM

– Relapsed/Refractory MDS Patients Achieved Median Overall Survival of 8.7 months –– Historically, Median Overall Survival in this Hard to Treat Patient Population is Only 4-6 Months1,2 –– Results Indicate

KPTI

4 minute read

2seventy bio To Present New Preclinical And Clinical Data From Broad Portfolio Of Investigational Cell Therapies At The ASGCT 26th Annual Meeting

By Benzinga Newsdesk

May 2, 4:55 PM

Late-breaking oral presentation will show early findings from Phase I PLAT-08 study of SC-DARIC33, an investigational, potentially first-in-class CD33-targeting CAR T in pediatric and young adults with

TSVT

2 minute read

Meta Quest Gaming Showcase 2023: What To Expect From The Exciting VR Event

By Franca Quarneti

May 1, 5:25 PM

Meta Quest, the line of virtual reality headsets developed by Meta Platforms Inc (NASDAQ: META), revealed the schedule for the third edition of its annual Gaming Showcase event, scheduled for 10 a.m. PT/1 p.m. ET on June 1, 2023.

Financial Whirlwind: 5 Stocks Feeling The Jitters Ahead Of Expected Fed Interest Rate Hike

By Piero Cingari

May 1, 5:03 PM

On Wednesday, the Federal Open Market Committee (FOMC) will almost definitely raise the Fed funds rate by 25 basis points to 4.75-5%, which might cause some market volatility, particularly for interest-rate sensitive equities.

AMT

2 minute read

Quantum Leap Healthcare Collaborative Announces Result Of Oral Paclitaxel In Combination With A PD-1 And Carboplatin From I-SPY2 TRIAL At ASCO

By Benzinga Newsdesk

May 1, 1:01 PM

Quantum Leap Healthcare Collaborative (Quantum Leap) and Athenex, Inc. (NASDAQ:ATNX) will present the findings of the I-SPY 2 TRIAL evaluation of Athenex's oral paclitaxel plus encequidar in combination with

ATNX